Medical Advocates
Etravirine (Intelence/TMC125)
  Journal Papers, Abstracts, and
Commentaries

In Vitro Data               Drug Comparison Studies
General Reports         Economics
Pharmacokinetics
Safety
Virology
Resistance
Drug/Drug Interactions
Diagnostics/Monitoring
Efficacy
Adverse Events
Therapeutic Strategies		  
Etravirine Main Page Main New/Newsworthy  Home Page      
Last Update:  February 05, 2012 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
In Vitro Data
 
 
Interaction potential of etravirine with drug transporters assessed in vitro.
Zembruski NC, Haefeli WE, Weiss J.
Antimicrob Agents Chemother. 2010 Dec 28.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility
in Treatment-Naive Patients and Week 48 Pooled DUET Study Data.
Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, et al 
AIDS Res Hum Retroviruses. 2010 May 27
Abstract

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro
selection experiments.
Vingerhoets J, Azijn H, Fransen E, et al
J Virol. 2005 Oct;79(20):12773-82.
Abstract
General Reports
 
 
Connection Domain Mutations in HIV-1 Reverse Transcriptase do not Impact Etravirine Susceptibility
and Virologic Responses to Etravirine-containing Regimens.
Gupta S, Vingerhoets J, Fransen S, et al.
Antimicrob Agents Chemother. 2011 Apr
Abstract

A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A, Calmy A, Delhumeau C,  et al
AIDS. 2010 Nov 11.
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals.
 Yeni P, Mills A, Peeters M, Vingerhoets J, et al
Curr HIV Res. 2010 Oct 13.
 Abstract

Etravirine: clinical review of a treatment option for HIV type-1-infected patients with
non-nucleoside reverse transcriptase inhibitor resistance.
Towner WJ, Cassetti I, Domingo P,  et al
Antivir Ther. 2010;15(6):803-16.
 Abstract

Etravirine: clinical review of a treatment option for HIV type-1-infected patients with
non-nucleoside reverse transcriptase inhibitor resistance.
 Towner WJ, Cassetti I, Domingo P,  et al
Antivir Ther. 2010;15(6):803-16.
 Abstract

Physicochemical properties of the amorphous drug, cast films, and spray dried powders
\to predict formulation probability of success for solid dispersions: Etravirine.
Weuts I, Van Dycke F, Voorspoels J
J Pharm Sci. 2010 Jun 22
 Abstract

Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125)
and Rilpivirine (TMC278): Implications for Drug Design.
Lansdon EB, Brendza KM, Hung M, et al
J Med Chem. 2010 May 3
 Abstract

Profile of etravirine for the treatment of HIV infection.
 Tseng A, Macarthur RD. 
Ther Clin Risk Manag. 2010 Feb 2;6:49-58.
 Abstract

Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human
immunodeficiency virus infection.
Elsayed RK, Caldwell DJ.
Am J Health Syst Pharm. 2010 Feb 1;67(3):193-205.
 Abstract

A WEEK-IN REVIEW FESTERED REPORT
Factors associated with virological response to etravirine in nonnucleoside reverse
transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, et al
Antimicrob Agents Chemother. 2010 Jan;54(1):72-7
 Abstract
 
Chemical characteristics, mechanism of action and antiviral activity of etravirine.
García FG, Estévez MA, Suay VG. 
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:2-5.
 Abstract
 
Etravirine in special populations
 Santos Gil ID.
 Enferm Infecc Microbiol Clin. 2009 Dec;27S2:40-45
 Abstract
 
Role of etravirine in combination antiretroviral therapy.
Domingo P.
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:46-51.
 Abstract

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009 Aug 13.
 Abstract

Etravirine: new drug. Multidrug-resistant HIV: another option.
[No authors listed]  
 Prescrire Int. 2009 Jun;18(101):102-3.
 Abstract

Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against
NNRTI-resistant strains of HIV.
Schiller DS, Youssef-Bessler M. 
Clin Ther. 2009 Apr;31(4):692-704.
 Abstract

Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhibitor.
Johnson LB, Saravolatz LD.
Clin Infect Dis. 2009 Mar 10
 Abstract

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against
human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP, McNicholl IR.
Pharmacotherapy. 2009 Mar;29(3):281-94
 Abstract
 
Raltegravir and Etravirine Are Active against HIV Type 1 Group O.
Briz V, Garrido C, Poveda E, et al 
AIDS Res Hum Retroviruses. 2009
Abstract
 
Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
 Covens K, Kabeya K, Schrooten Y, et al
 J Clin Virol. 2009 Feb 21.
Abstract
 
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
Jayaweera DT, Espinoza L, Castro J.
Expert Opin Pharmacother. 2008 Dec;9(17):3083-94.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M, Boffito M, et al
Pharmacotherapy. 2008 Oct;28(10):1215-22.
 Abstract
 
Etravirine for the treatment of HIV infection.
Seminari E, Castagna A, Lazzarin A. 
Expert Rev Anti Infect Ther. 2008 Aug;6(4):427-33.
 Abstract

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor
resistance?
Scott C, Grover D, Nelson M.  
AIDS. 2008 May 11;22(8):989-90.
 Abstract
 
Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers (June).
Peeters M, Janssen K, Kakuda TN, et al
Ann Pharmacother. 2008 Apr 29
Abstract
 
Etravirine.
Knoll BM, Vento S, Temesgen Z. 
Drugs Today (Barc). 2008 Jan;44(1):23-33
 Abstract

FULL-TEXT ARTICLE
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against
nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K, Azijn H, Thielemans T, et al
 Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.
 Paper

Roles of conformational and positional adaptability in structure-based design of TMC125-R165335
(etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and
effective against wild-type and drug-resistant HIV-1 variants.
Das K, Clark AD Jr, Lewi PJ, et al
J Med Chem. 2004 May 6;47(10):2550-60.
Abstract
Pharmacokinetics
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected
children and adolescents.
 Königs C, Feiterna-Sperling C, Esposito S,  et al
AIDS. 2011 Dec 7
 Abstract

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine t
wice daily in HIV-infected patients.
Gutiérrez-Valencia A, Martin-Peña R, et al
J Antimicrob Chemother. 2011 Dec 21
 Abstract

Darunavir, Ritonavir and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood
Plasma of HIV-Infected Women
Patterson K, Jennings S, Falcon R,  et al
Antimicrob Agents Chemother. 2010 Dec 20
 Abstract

Pharmacokinetic evaluation of etravirine.
Dickinson L, Khoo S, Back D.
 Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1575-1585.
 Abstract

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L,  et al
AIDS. 2010 Oct 23;24(16):2581-3.
 Abstract

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase
Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients.
Kakuda TN, Wade JR, Snoeck E,  et al
Clin Pharmacol Ther. 2010 Sep 29.
 Abstract

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir
in antiretroviral-naive HIV type-1-infected adults.
DeJesus E, Lalezari JP, Osiyemi OO,  et al
Antivir Ther. 2010;15(5):711-20.
 Abstract

Clinical pharmacokinetics and pharmacodynamics of etravirine.
Schöller-Gyüre M, Kakuda TN, Raoof A, et al 
Clin Pharmacokinet. 2009;48(9):561-74
 Abstract

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily
After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M, et al
J Acquir Immune Defic Syndr. 2009 Jul 17
 Abstract

Single- and multiple-dose pharmacokinetics of etravirine administered as two different
 formulations in HIV-1-infected patients.
Kakuda TN, Schöller-Gyüre M,  
Antivir Ther. 2008;13(5):655-61.
 Abstract

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in
HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
Br J Clin Pharmacol. 2008 May 19
 Abstract

Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of
Methadone and TMC125 in HIV-Negative Volunteers.
 Schöller-Gyüre M, van den Brink W, et al
J Clin Pharmacol. 2008 Jan 14
Abstract
Safety
 
 

 
Efficacy and Safety Outcomes Among Treatment-Experienced Men and Women Treated with  Etravirine in GRACE (Gender, Race AND Clinical Experience).
Hodder S, Jayaweera D, Mrus JM,  et al
 AIDS Res Hum Retroviruses. 2011 Dec 29.
 Abstract

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients:
pooled 96 week results from the Phase III DUET trials.
Clotet B, Clumeck N, Katlama C, et al
J Antimicrob Chemother. 2010 Aug 27
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A Review of the Safety and Tolerability Profile of the Next-Generation
NNRTI Etravirine.
Grinsztejn B, Di Perri G, Towner W, et al
AIDS Res Hum Retroviruses. 2010 Jul 12.
 Abstract

Safety and tolerability of etravirine.
Portilla J.  
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:21-26
 Abstract
Virology
 
 

 
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N, Cahn P, Molina JM, et al
Int J STD AIDS. 2010 Nov;21(11):738-40.
 Abstract

Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis
of DUET-1 and -2.
Trottier B, Di Perri G, Madruga JV,  et al
HIV Clin Trials. 2010 Jul-Aug;11(4):175-85
 Abstract
Resistance
 
 
A WEEK-IN REVIEW FEATURED REPORT
Emerging mutations and associated factors in patients displaying treatment failure on an
etravirine-containing regimen.
Marcelin AG, Descamps D, Tamalet C,  et al
Antivir Ther. 2012;17(1):119-123.
 Abstract

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside
reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J, Chetchotisakd P,  et al
Antivir Ther. 2011;16(7):1113-21
 Abstract

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine:
effects on fitness and RT activity of human immunodeficiency virus type 1.
Hu Z, Kuritzkes DR.
J Virol. 2011 Aug 17.
Abstract

Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility |
and Virologic Response to Etravirine.
Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J.
 J Acquir Immune Defic Syndr. 2011 Jun 2
 Abstract

Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples Received for
Routine HIV-1 Resistance Testing in the USA.
 Picchio G, Vingerhoets J, Tambuyzer L, et al
AIDS Res Hum Retroviruses. 2011 May 10
 Abstract

Predicted susceptibility of etravirine in HIV patients experiencing virological failure
secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
Córdova E, Loiza E, Porteiro N, Mingrone H.
 Enferm Infecc Microbiol Clin. 2011 May 16.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Resistance analyses in highly experienced patients failing raltegravir, etravirine
and darunavir/ritonavir regimen.
 Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
 Abstract

Prevalence of mutations and determinants of genotypic resistance to etravirine
(TMC125) in a large Italian resistance database (ARCA)dagger.
Di Vincenzo P, Rusconi S, Adorni F, et al
HIV Med. 2010 Mar 8
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated
mutations in the DUET trials.
 Peeters M, Vingerhoets J, Tambuyzer L, et al 
AIDS. 2010 Feb 12.
Abstract.

A WEEK-IN-REVIEW FEATURED REPORT
Resistance profile of etravirine: combined analysis of baseline genotypic and
phenotypic data from the randomized, controlled Phase III clinical studies.
Vingerhoets J, Tambuyzer L, Azijn H,  et al
AIDS 2010 Jan 5.
 Abstract.

A WEEK-IN-REVIEW FEATURED REPORT
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care:
the Swiss HIV Cohort Study (SHCS).
Scherrer AU, Hasse B, von Wyl V,  et al 
HIV Med. 2009 Sep 1
 Abstract

HIV-1 recombinant reverse transcriptase enzymes containing the G190A and
Y181C resistance mutations remain sensitive to etravirine.
Xu H, Quan Y, Brenner BG, Bar-Magen T, et al 
Antimicrob Agents Chemother. 2009 Aug 24
 Abstract

Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine
in clinical samples.
Kagan RM, Sista P, Pattery T, et al 
AIDS. 2009 May 25
 Abstract

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
Cotte L, Trabaud MA, Tardy JC, et al 
J Med Virol. 2009 Feb 23;81(4):672-677
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to
nonnucleoside analogues.
Poveda E, de Mendoza C, Pattery T, et al
AIDS. 2008 Nov 12;22(17):2395-8.
 Abstract
 
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase
inhibitors.
Lapadula G, Calabresi A, Castelnuovo F, et al  
Antivir Ther. 2008;13(4):601-5.
 Abstract

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Llibre JM, Santos JR, Puig T, et al
J Antimicrob Chemother. 2008 Jul 23.
Abstract
Drug/Drug Interactions
 
 
Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Do VT, Higginson RT, Fulco PP.
 Am J Health Syst Pharm. 2011 Nov 1
 Abstract

The Effect of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics
of Dolutegravir.
Song I, Borland J, Min S, et al  
Antimicrob Agents Chemother. 2011 May
Abstract

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and
norethindrone.
Schöller-Gyüre M, Kakuda TN, Woodfall B, et al 
Contraception. 2009 Jul;80(1):44-52.
Abstract

Minimal Pharmacokinetic Interaction Between the HIV Non-Nucleoside Reverse Transcriptase Inhibitor Etravirine
and the Integrase Inhibitor Raltegravir in Healthy Subjects.
Anderson MS, Kakuda TN, Hanley W, et al   
Antimicrob Agents Chemother. 2008 Oct 6.
 Abstract
 
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in
HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
Br J Clin Pharmacol. 2008 May 19
 Abstract

Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of
Methadone and TMC125 in HIV-Negative Volunteers.
Schöller-Gyüre M, van den Brink W, et al
J Clin Pharmacol. 2008 Jan 14
Abstract
Diagnostics/Monitoring
 
 
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine,
raltegravir and ritonavir in dried blood spot samples.
Ter Heine R, Mulder JW, van Gorp EC, et al
Bioanalysis. 2011 May;3(10):1093-7
 Abstract

A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir,
maraviroc, darunavir, and etravirine.
Fayet A, Béguin A, Zanolari B, Cruchon S, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 28
 Abstract

Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate
by liquid chromatography tandem mass spectrometry.
 Ter Heine R, Rosing H, van Gorp EC, et al
J Pharm Biomed Anal. 2008 Nov 5.
Abstract
Efficacy
 
 
Efficacy and Safety Outcomes Among Treatment-Experienced Men and Women Treated with  Etravirine in GRACE (Gender, Race AND Clinical Experience).
 Hodder S, Jayaweera D, Mrus JM,  et al
 AIDS Res Hum Retroviruses. 2011 Dec 29.
 Abstract

Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in Treatment-Experienced Patients: A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic). 2011 Mar 23
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
High effectiveness of etravirine in routine clinical practice in treatment-experienced
HIV-1-infected patients.
Santos JR, Llibre JM, Domingo P,  et al
AIDS Res Hum Retroviruses. 2010 Nov 30.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected
patients in the DUET-1 and DUET-2 trials.
Katlama C, Clotet B, Mills A, et al
Antivir Ther. 2010;15(7):1045-52
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Etravirine in combination with darunavir/ritonavir and optimized background
regimen results in suppression of HIV replication in treatment-experienced
patients Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy
and safety of etravirine in treatment-experienced HIV-1 patients: pooled
48-week analysis of two randomized, controlled trials. AIDS 2009;23:2289 300.
Hull MW, Montaner JS.  
Expert Opin Pharmacother. 2010 Apr 3
 Abstract

A WEEK-IN REVIEW FESTERED REPORT
Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir
or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early |
Access Program in the United States.
Towner W, Lalezari J, Sension MG, et al
J Acquir Immune Defic Syndr. 2010 Feb 3
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir
and raltegravir in the etravirine early access programme.
Florence E, De Wit S, Castagna A,  et al
 Int J STD AIDS. 2010 Jan 13.
 Abstract

Role of etravirine in combination antiretroviral therapy.
 Domingo P.
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:46-51.
 Abstract
 
Etravirine in first-line therapy
Garcés PA, Tena EV.  
Enferm Infecc Microbiol Clin. 2009 Dec;27S2:12-20
Abstract
 

A WEEK IN REVIEW FEATURED REPORT
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis
of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, et al 
AIDS. 2009 Aug 25.
Abstract

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily
After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
 Boffito M, Jackson A, Lamorde M,  et al  
J Acquir Immune Defic Syndr. 2009 Jul 17|
 Abstract

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically
HIV-1 infection.
 Rosso R, Bernardini C, Bruzzone B, et al 
Eur J Med Res. 2009 Mar 17;14(3):136-8.
 Abstract

Efficacy of Etravirine for Treatment of Acute HIV Meningoencephalitis.
Couzigou C, Seang S, Morand-Joubert L, et al 
Clin Infect Dis. 2009 Feb 1
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients:
48-week results of a phase IIb trial.
Cohen CJ, Berger DS, Blick G, et al 
AIDS. 2008 Dec 24
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial
non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Sungkanuparph S, Manosuthi W, Kiertiburanakul S,et al
Curr HIV Res. 2008 Sep;6(5):474-6
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside
reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase
inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro R, Latiff G, et al 
HIV Med. 2008 Sep 14.
 Abstract
 
Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb
Dose-Ranging Study Involving Treatment-Experienced Patients with HIV-1 Infection.
Montaner J, Yeni P, Clumeck NN, et al
Clin Infect Dis. 2008 Sep 2.
Abstract
 
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in
DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A, Campbell T, Clotet B, et al 
Lancet. 2007 Jul 7;370(9581):39-48.
 Abstract
 
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in
DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, et al
Lancet. 2007 Jul 7;370(9581):29-38.
 Abstract

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary
24-week analysis.
The TMC125-C223 Writing Group.
 AIDS. 2007 Mar 30;21(6):F1-F10.
 Abstract

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Sankatsing SU, Weverling GJ, Peeters M, et al
AIDS. 2003 Dec 5;17(18):2623-7
Abstract

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in
antiretroviral naive, HIV-1 infected subjects.
Gruzdev B, Rakhmanova A, Doubovskaya E, et al
AIDS. 2003 Nov 21;17(17):2487-94.
 Abstract
Adverse Events
 
 
A WEEK-IN-REVIEW FEATURED REPORT
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine
and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M, Stellbrink HJ, Podzamczer D, et al
AIDS. 2010 Dec 9.
Abstract
Therapeutic Strategies
 
 
FULL-TEXT PDF ARTICLE
 Marked increase in etravirine and saquinavir plasma concentrations
during atovaquone/proguanil prophylaxis
Tommasi C, Bellagamba R, Tempestilli M, et al
Malar J. 2011 May 21;10(1):141.
Paper

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess
the feasibility of switching individuals receiving efavirenz with continuing central nervous system
adverse events to etravirine.
Waters L, Fisher M, Winston A,   et al
AIDS. 2010 Nov 19
 Abstract

A 48-Week Pilot Study Switching Suppressed Patients to Darunavir/Ritonavir and
Etravirine from Enfuvirtide, Protease Inhibitor(s), and Non-nucleoside Reverse
Transcriptase Inhibitor(s).
 Ruane P, Alas B, Ryan R, et al
 AIDS Res Hum Retroviruses. 2010 Nov;26(11):1215-1219.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside
reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected
patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A,  et al
 AIDS. 2010 Feb 11
 Abstract
Drug Comparison Studies
 
 
A WEEK-IN REVIEW FEATURED REPORT
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized,
double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A,  et al
J Antimicrob Chemother. 2011 Dec 29.
 Abstract

Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naïve patients: 48 week results.
Gazzard B, Duvivier C, Zagler C,  et al
AIDS. 2011 Aug 30.
Abstract
Economics
 
 
Cost-effectiveness of Combination Therapy With Etravirine in Treatment-Experienced Adults
With HIV-1 Infection in Canada.
Mauskopf J, Brogan AJ, Talbird SE, Martin S
 AIDS. 2011 Nov 14.
Abstract

 
Etravirine Main Page Main New/Newsworthy  Home Page      

Etravirine Journal Citations